Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice

#2757

Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.

Aim(s): The PanNET Study aims to describe the effectiveness estimating the progression-free survival (PFS) at 24 months after treatment initiation with LAN every 28 days in a real-world population of patients with advanced or metastatic panNETs

Materials and methods: This is a non-interventional, multicentre, prospective study with retrospective data collection (from treatment initiation to the inclusion visit) under routine clinical practice conditions. The study will enroll adults with non-progressive functioning or non-functioning panNET grade 1 and 2 (Ki-67 ≤10%) with unresectable locally advanced tumours or metastatic disease and treated with LAN every 28 days for 3–12 months. It is planned to recruit 196 patients in about 45 sites and follow them up for up to 21 months or until death or treatment discontinuation. The primary endpoint will be the investigator-assessed PFS rate at 24 months after initiation of LAN. Secondary endpoints include panNET history management, prognostic factors of PFS, quality of life, and safety profile.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Teulé A, Alonso T, González E, De La Cruz G, Houchard A,

Keywords: NET, lanreotide, pancreas, study,